Trial Profile
A Phase II Study of Sporadic Angiomyolipomas (AMLs) Growth Kinetics While on Everolimus Therapy
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Angiomyolipoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms SAGE
- Sponsors Novartis Pharmaceuticals Corporation
- 06 Apr 2020 Results published in the Journal of Urology
- 13 Sep 2018 Status changed from recruiting to discontinued due to extreme toxicity, met toxicity stopping rules
- 08 Sep 2017 Planned End Date changed from 1 Jul 2017 to 1 Jul 2019.